Psychedelic Therapy
Training for Canadians in Medical Need
We are TheraPsil — Canada’s leading psychedelic organization, bringing together healthcare practitioners, patients, community members and advocates to provide hope and healing through psychedelic therapy.
Our Story
Founded in 2019 by Dr. Bruce Tobin, TheraPsil emerged from a deep understanding of the mental health challenges faced by Canadians. Driven by a commitment to compassionate, human-centred care, we are dedicated to helping Canadians in medical need access psychedelic-assisted psychotherapy with the support of qualified healthcare professionals.
Our Vision
TheraPsil is establishing a trusted ecosystem of psychedelic healthcare to ensure safe and effective psilocybin and MDMA-assisted psychotherapy.
We envision a future where every Canadian has equitable and regulated access to psychedelic treatments.
Our Pillars
EDUCATION
Our dedicated team is committed to educating both healthcare professionals and the general public about the merits and limitations of psychedelic-assisted psychotherapy. Through comprehensive professional training, we provide safe and effective treatment protocols for healthcare professionals and organizations to deliver psilocybin and MDMA-assisted psychotherapy. We work to increase public awareness of medical rights and share knowledge of psychedelics’ proven benefits in healthcare.
COMMUNITY
TheraPsil is actively building an inclusive Community of Care and Practice, where individuals can connect, share experiences, and find support when working with psychedelics. We prioritize the engagement and empowerment of diverse voices in creating a community rooted in empathy, compassion, and human-centered care.
ADVOCACY
At the core of TheraPsil is our grassroots advocacy for equitable, safe and subsidized access to psychedelics. We empower individuals to choose therapies that can improve their personal and mental wellbeing and fearlessly challenge the laws that are in conflict with science and compassionate care. We are also dedicated to collaborative research initiatives, advancing the field of psychedelic-assisted therapies
